Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

HighTide Plans Hong Kong IPO to Support Metabolic and Digestive Portfolio

publication date: Jun 9, 2023

Shenzhen HighTide Therapeutics filed for an IPO on the Hong Kong Exchange to develop a portfolio of novel multifunctional drugs for metabolic and digestive diseases. The company’s lead candidate is berberine ursodeoxycholate, a gut-liver anti-inflammatory metabolic modulator that targets multiple pathways. HTD1801 is being developed for nonalcoholic steatohepatitis (NASH), type 2 diabetes and three other indications. The company is developing five assets for nine indications. Founded in 2011, HighTide was originally backed by Hepalink and its Chairman/CEO, Dr. Liu. In January 2023, HighTide closed a $107 million Series C/C+ funding. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital